Objective To provide guidance to rheumatology providers on the use of coronavirus disease
2019 (COVID‐19) vaccines for patients with rheumatic and musculoskeletal diseases …

Development of Interferon-Gamma Release Assays (IGRAs) and implementation of their use
in clinical practice almost 10years ago has revolutionised diagnosis of latent tuberculosis …

Objective To provide guidance to rheumatology providers on the use of COVID‐19 vaccines
for patients with rheumatic and musculoskeletal diseases (RMDs). Methods A task force was …

Objective To provide guidance to rheumatology providers on the use of COVID‐19 vaccines
for patients with rheumatic and musculoskeletal diseases (RMDs). Methods A task force was …

Biologicals revolutionized the treatment of Rheumatoid Arthritis (RA). The targeted
suppression of key inflammatory pathways involved in joint inflammation and destruction …

Background During screening for latent tuberculosis infection (LTBI), before anti-tumor-
necrosis-factor-α treatment, most patients are already receiving immunosuppressive …

Background Accurate diagnosis and subsequent treatment of latent tuberculosis infection
(LTBI) is essential for TB elimination. However, the absence of a gold standard test for …

Objectives To investigate the risk factors for false-negative T-SPOT. TB results in patients
with pulmonary TB (PTB) and extra-pulmonary TB (EPTB). Methods Patients with suspected …

Objective To evaluate the performance of an interferon‐γ release assay (IGRA) versus the
standard tuberculin skin test (TST) as a screening tool for latent tuberculosis (TB) infection …

Background Targeted screening for latent TB infection (LTBI) in vulnerable populations is a
recommended TB control strategy. Pregnant women are at high risk for developing TB and …